American Association for Cancer Research

sorry, we can't preview this file

23266066cir180266-sup-199043_3_supp_5215039_pjj9xf.docx (21.92 kB)

Supplementary Figure Legends from A Mechanism of Resistance to Antibody-Targeted Immune Attack

Download (21.92 kB)
journal contribution
posted on 2023-04-03, 23:21 authored by Dalal S. Aldeghaither, David J. Zahavi, Joseph C. Murray, Elana J. Fertig, Garrett T. Graham, Yong-Wei Zhang, Allison O'Connell, Junfeng Ma, Sandra A. Jablonski, Louis M. Weiner

Legends for Supplemental Figures 1-7 in Supplementary Data file





Targeted monoclonal antibody therapy is a promising therapeutic strategy for cancer, and antibody-dependent cell-mediated cytotoxicity (ADCC) represents a crucial mechanism underlying these approaches. The majority of patients have limited responses to monoclonal antibody therapy due to the development of resistance. Models of ADCC provide a system for uncovering immune-resistance mechanisms. We continuously exposed epidermal growth factor receptor (EGFR+) A431 cells to KIR-deficient NK92-CD16V effector cells and the anti-EGFR cetuximab. Persistent ADCC exposure yielded ADCC-resistant cells (ADCCR1) that, compared with control ADCC-sensitive cells (ADCCS1), exhibited reduced EGFR expression, overexpression of histone- and interferon-related genes, and a failure to activate NK cells, without evidence of epithelial-to-mesenchymal transition. These properties gradually reversed following withdrawal of ADCC selection pressure. The development of resistance was associated with lower expression of multiple cell-surface molecules that contribute to cell–cell interactions and immune synapse formation. Classic immune checkpoints did not modulate ADCC in this unique model system of immune resistance. We showed that the induction of ADCC resistance involves genetic and epigenetic changes that lead to a general loss of target cell adhesion properties that are required for the establishment of an immune synapse, killer cell activation, and target cell cytotoxicity.